Korean Approval Received by Kolon Life Science, TissueGene’s Exclusive Licensee

Our partner BioLife Solutions, Inc. (NASDAQ: BLFS), the leading supplier of pre-formulated, clinical grade cell and tissue hypothermic storage and cryopreservation freeze media (“BioLife”), announced on that Kolon Life Science, TissueGene’s exclusive licensee for Asia, including Korea, has received marketing approval for Invossa-K Inj., the world’s first cell and gene therapy for degenerative arthritis from the Korea Ministry of Food and Drug Safety (MFDS).The manufactured Invossa cell and gene therapy will be frozen and shipped in BioLife’s CryoStor cell freeze media to extend the shelf life until arrival at the clinic for injection into the patient.

To read more, please click here

Leave a Reply

Your email address will not be published. Required fields are marked